[关键词]
[摘要]
目的： 评价贝伐单抗注射治疗初发翼状胬肉的临床疗效及安全性。
方法：选取2012-05/2013-04在我院眼科门诊就诊的初发翼状胬肉患者66例66眼随机分为两组，试验组34眼行病灶内注射贝伐单抗1.25mg/次，1次/mo，共三次，对照组32眼予人工泪液及非甾体抗炎滴眼液滴眼。
结果： 随访6mo，试验组与对照组胬肉充血程度及厚度均较基线水平下降，两组差异有统计学意义(P<0.05)； 视力、眼压、胬肉百分比与基线水平比较均无统计学差异(P>0.05)。
结论：贝伐单抗病灶内注射可有效控制初发翼状胬肉至少6mo，未见明显眼部及全身并发症。
[Key word]
[Abstract]
AIM: To evaluate the clinical efficacy and safety of intralesional injection of bevacizumab on primary pterygium treatment.
METHODS: A total of 66 patients(66 eyes)from May, 2012 to April, 2013 were randomized into 2 groups. The treatment group(34 eyes)was received an intralesional injection of bevacizumab 1.25mg(100mg/4mL)each time, once a month, a total of three times. The control group(32 eyes)was received a combination of artificial tears and non-steroidal anti-inflammatory eye drops.
RESULTS: After 6mo follow-up, it was showed that there was a statistically significant reduction of injection and the elevation of pterygium was compared with the baseline in both groups(P<0.05). There was no significant difference of vision, intraocular pressure and percentage of corneal pterygium compared with the baseline in both groups(P>0.05).
CONCLUSION:Intralesional bevacizumab can control primary pterygium effectively for at least 6mo with no serious ocular or systemic adverse effects.
[中图分类号]
[基金项目]
